Last reviewed · How we verify
Aprepitant plus Olanzapine
Aprepitant plus Olanzapine is a NK1 receptor antagonist + atypical antipsychotic combination Small molecule drug developed by Rush University Medical Center. It is currently in Phase 3 development for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy. Also known as: Emend, Zyprexa.
Aprepitant blocks substance P neurokinin-1 receptors while olanzapine antagonizes dopamine and serotonin receptors, together providing enhanced antiemetic and anti-nausea effects.
Aprepitant blocks substance P neurokinin-1 receptors while olanzapine antagonizes dopamine and serotonin receptors, together providing enhanced antiemetic and anti-nausea effects. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Aprepitant plus Olanzapine |
|---|---|
| Also known as | Emend, Zyprexa |
| Sponsor | Rush University Medical Center |
| Drug class | NK1 receptor antagonist + atypical antipsychotic combination |
| Target | Neurokinin-1 (NK1) receptor; dopamine D2 receptor; serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Aprepitant is a selective neurokinin-1 (NK1) receptor antagonist that crosses the blood-brain barrier to block substance P signaling in chemotherapy-induced nausea and vomiting (CINV) pathways. Olanzapine is an atypical antipsychotic with dopamine D2 and serotonin 5-HT2A antagonism that contributes additional antiemetic activity. The combination targets multiple pathways involved in emesis, particularly for highly emetogenic chemotherapy regimens.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy
Common side effects
- Somnolence
- Fatigue
- Dizziness
- Constipation
- Weight gain
Key clinical trials
- Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer (PHASE3)
- Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy (PHASE3)
- Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer (PHASE3)
- Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy (PHASE3)
- Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan (PHASE3)
- Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV (PHASE3)
- Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents (PHASE3)
- The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aprepitant plus Olanzapine CI brief — competitive landscape report
- Aprepitant plus Olanzapine updates RSS · CI watch RSS
- Rush University Medical Center portfolio CI
Frequently asked questions about Aprepitant plus Olanzapine
What is Aprepitant plus Olanzapine?
How does Aprepitant plus Olanzapine work?
What is Aprepitant plus Olanzapine used for?
Who makes Aprepitant plus Olanzapine?
Is Aprepitant plus Olanzapine also known as anything else?
What drug class is Aprepitant plus Olanzapine in?
What development phase is Aprepitant plus Olanzapine in?
What are the side effects of Aprepitant plus Olanzapine?
What does Aprepitant plus Olanzapine target?
Related
- Drug class: All NK1 receptor antagonist + atypical antipsychotic combination drugs
- Target: All drugs targeting Neurokinin-1 (NK1) receptor; dopamine D2 receptor; serotonin 5-HT2A receptor
- Manufacturer: Rush University Medical Center — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy
- Also known as: Emend, Zyprexa
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing